Edgewise Therapeutics Inc (EWTX) Stock Price, Quote & News

Company Profile

Edgewise Therapeutics, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapies for the treatment of muscle disorders. Its lead product candidate, EDG-5506, an orally administered small molecule that is in Phase II clinical trials, designed to address the root cause of dystrophinopathies including Duchenne muscular dystrophy and Becker muscular dystrophy. The company develops EDG-7500, a small molecule for the treatment of hypertrophic cardiomyopathy and other severe...

Industry: Biotechnology

Sector: Healthcare

Phone: 720 262 7002

Website: edgewisetx.com

Address:

1715 38th Street, Boulder, United States

topstockalerts Dec. 25 at 3:26 PM

After Hours Top Gainers PT2 $INDP $SIDU $FMFC $IZM $EWTX

0 · Reply

SharpeRatioS Dec. 25 at 8:37 AM

$EWTX The valuation debate now centers on reliability of delivery, given the heightened sensitivity to timeline slippage. Delivery cadence is becoming the real competitive edge.

0 · Reply

WallStreetBuyDip Dec. 25 at 4:23 AM

Comparing trending tickers $EWTX vs $AGQ: EWTX surged 25.47% to $27.29 on a trading volume of 3.6M shares, significantly above its average of 1.2M. In comparison, AGQ modestly increased by 1.02% to $167.68 with a volume of 3.9M shares, slightly above its usual 2.4M. EWTX is showing more dramatic price movement relative to its volume increase compared to AGQ, which saw less pronounced price changes despite high trading activity.

0 · Reply

WallStreetBuyDip Dec. 25 at 4:02 AM

Comparing trending tickers $D vs $EWTX: "D rose modestly today by 1.50% to $59.01, with trading volume reaching 3.1 million shares, a bit below its average of 5.3 million. In contrast, EWTX surged by 25.47% to $27.29 on a volume of 3.6 million shares, significantly above its usual 1.2 million shares. EWTX's performance today not only shows a substantial price jump but also a dramatic increase in trading activity compared to its norm, outpacing D in both price movement and relative volume spike."

0 · Reply

Ohzipit Dec. 25 at 12:40 AM

$EWTX Raymond James -We Usually Do Gifts in the Evening, but Glad We Opened This One Early; Reiterate Strong Buy

1 · Reply

topstockalerts Dec. 24 at 10:37 PM

Top Gainers PT2 $INDP $SIDU $FMFC $IZM $EWTX

0 · Reply

topstockalerts Dec. 24 at 8:48 PM

After Hours Top Gainers PT2 $INDP $SIDU $FMFC $IZM $EWTX

0 · Reply

AStrokeOfLuck Dec. 24 at 6:45 PM

$EWTX

0 · Reply

topstockalerts Dec. 24 at 6:23 PM

Top Gainers PT2 $INDP $SIDU $FMFC $IZM $EWTX

0 · Reply

topstockalerts Dec. 24 at 5:57 PM

$EWTX heading for a strong close..

0 · Reply

Edgewise Therapeutics Announces Completion of the EDG-7500 CIRRUS-HCM Phase 2 Parts B and C and Favorable Interim Safety Results from the Ongoing Part D Study in Hypertrophic Cardiomyopathy

Dec 4, 2025, 3:53 AM EST - 21 days ago

Edgewise Therapeutics, Inc. (EWTX) Presents at Piper Sandler 37th Annual Healthcare Conference Transcript

Dec 2, 2025, 8:00 AM EST - 23 days ago

Edgewise Therapeutics Reports Inducement Grants as permitted by the Nasdaq Listing Rules

Nov 20, 2025, 8:00 AM EST - 5 weeks ago

Edgewise Therapeutics Appoints Commercial Biotech Executive Christopher Martin to its Board of Directors

Nov 10, 2025, 8:00 AM EST - 6 weeks ago

Edgewise Therapeutics Announces Appointment of Michael Nofi as Chief Financial Officer, and the Retirement of Current CFO, R. Michael Carruthers

Nov 7, 2025, 8:00 AM EST - 6 weeks ago

Edgewise Therapeutics to Participate in Upcoming Investor Conferences

Nov 6, 2025, 8:00 AM EST - 7 weeks ago

Edgewise Therapeutics Reports Third Quarter 2025 Financial Results and Recent Business Highlights

Oct 2, 2025, 8:00 AM EDT - 3 months ago

Edgewise Therapeutics to Present on Sevasemten for Becker and Duchenne Muscular Dystrophies at the 30th International Annual Congress of the World Muscle Society

Aug 14, 2025, 3:53 PM EDT - 4 months ago

Edgewise Therapeutics, Inc. Investors: Company Investigated by the Portnoy Law Firm

Aug 7, 2025, 8:00 AM EDT - 5 months ago

Edgewise Therapeutics Reports Second Quarter 2025 Financial Results and Recent Business Highlights

Jul 19, 2025, 6:58 PM EDT - 5 months ago

EWTX Investors Have Opportunity to Join Edgewise Therapeutics, Inc. Fraud Investigation with the Schall Law Firm

Jun 26, 2025, 6:00 AM EDT - 6 months ago

Edgewise Therapeutics Reports Positive Results on Sevasemten Program for Becker and Duchenne Muscular Dystrophies

Jun 3, 2025, 8:00 AM EDT - 7 months ago

Edgewise Therapeutics to Present at the Annual Goldman Sachs Global Healthcare Conference

May 14, 2025, 8:00 AM EDT - 8 months ago

Edgewise Therapeutics to Present at the RBC Capital Markets Global Healthcare Conference on May 20, 2025

May 8, 2025, 8:00 AM EDT - 8 months ago

Edgewise Therapeutics Reports First Quarter 2025 Financial Results and Recent Business Highlights

Apr 10, 2025, 6:56 AM EDT - 9 months ago

Top 3 Health Care Stocks That Could Lead To Your Biggest Gains In Q2

CAMP

Apr 2, 2025, 4:54 PM EDT - 9 months ago

Edgewise Therapeutics: Despite AF Safety Issues, EDG-7500 Advancement Presses On

Apr 2, 2025, 12:27 PM EDT - 9 months ago

Edgewise Therapeutics Sees Meaningful HCM Treatment Gains With EDG-7500 In Phase 2 Study

Apr 2, 2025, 6:22 AM EDT - 9 months ago

Edgewise Therapeutics Announces Pricing of $200 Million Underwritten Offering of Common Stock

Apr 2, 2025, 6:00 AM EDT - 9 months ago

Edgewise Therapeutics Announces Positive Top-Line Results from Phase 2 CIRRUS-HCM Four-Week Trial of EDG-7500 in Hypertrophic Cardiomyopathy (HCM)

Mar 26, 2025, 4:45 PM EDT - 9 months ago

Edgewise Therapeutics to Host Webcast Event to Discuss Top-Line Results from Phase 2 CIRRUS-HCM 28-Day Trial of EDG-7500 in Hypertrophic Cardiomyopathy (HCM) on Wednesday, April 2 at 8:30 am Eastern Time

Mar 11, 2025, 8:00 AM EDT - 10 months ago

Edgewise Therapeutics to Present on Sevasemten for the Treatment of Becker Muscular Dystrophy at the 2025 MDA Clinical and Scientific Conference

Mar 10, 2025, 1:36 PM EDT - 10 months ago

Edgewise Therapeutics: More Expensive Now, But Much More Derisked

Mar 4, 2025, 8:00 AM EST - 10 months ago

Edgewise Therapeutics to Present at the Leerink Partners Global Healthcare Conference on March 11, 2025

Mar 3, 2025, 8:00 AM EST - 10 months ago

Edgewise Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Business Highlights

Jan 22, 2025, 8:00 AM EST - 1 year ago

Edgewise Therapeutics Strengthens Leadership Team to Support Late-Stage Clinical Development

Jan 13, 2025, 8:00 AM EST - 1 year ago

Edgewise Therapeutics Provides Corporate Update and Highlights Priorities for 2025

Jan 7, 2025, 8:00 AM EST - 1 year ago

Edgewise Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference on January 13, 2025

Dec 31, 2024, 2:09 PM EST - 1 year ago

Edgewise: Remains A Buy After Latest Becker Muscular Dystrophy Data

Dec 16, 2024, 11:56 AM EST - 1 year ago

Edgewise Therapeutics' Lead Candidate Reduces Biomarker Levels In Mid-Stage Study In Patients With Muscle Weakness Disease

Dec 16, 2024, 6:00 AM EST - 1 year ago

Edgewise Therapeutics Announces Positive Topline Results from the CANYON Phase 2 Trial of Sevasemten in Individuals with Becker Muscular Dystrophy (Becker)

Dec 5, 2024, 2:32 PM EST - 1 year ago

Edgewise Provides Statement Regarding Company's Relationship with Dr. Han Phan at Rare Disease Research

Nov 26, 2024, 6:00 AM EST - 1 year ago

Edgewise Therapeutics to Present at the Piper Sandler 36th Annual Healthcare Conference on December 3, 2024

Nov 7, 2024, 8:00 AM EST - 1 year ago

Edgewise Therapeutics Reports Third Quarter 2024 Financial Results and Recent Business Highlights

Oct 1, 2024, 8:00 AM EDT - 1 year ago

Edgewise Therapeutics to Present on Sevasemten (EDG-5506) for Becker Muscular Dystrophy (Becker) at the 29th International Annual Congress of the World Muscle Society

Sep 30, 2024, 12:12 PM EDT - 1 year ago

Analysts Think There's Still Time To Get In On Edgewise

Sep 25, 2024, 11:50 AM EDT - 1 year ago

Edgewise Therapeutics Soars 50%: Key Reasons Behind the Surge

Sep 19, 2024, 10:19 AM EDT - 1 year ago

Edgewise Therapeutics Stock Shoots Higher On Promising Early Results For Thickened Heart Treatment

Sep 19, 2024, 7:00 AM EDT - 1 year ago

Edgewise Therapeutics Announces Positive Top-Line Data from Phase 1 Trial in Healthy Subjects and Phase 2 CIRRUS-HCM Trial in Patients with Obstructive Hypertrophic Cardiomyopathy (HCM)

Sep 17, 2024, 4:01 PM EDT - 1 year ago

Edgewise Therapeutics to Host Webcast Event to Discuss Top-Line Data from Phase 1 trial in Healthy Subjects and Phase 2 CIRRUS-HCM Trial in Patients with Obstructive Hypertrophic Cardiomyopathy (HCM) on Thursday, September 19 at 8:30 am Eastern Time

Aug 8, 2024, 8:00 AM EDT - 1 year ago

Edgewise Therapeutics Reports Second Quarter 2024 Financial Results and Recent Business Highlights

Aug 5, 2024, 2:38 PM EDT - 1 year ago

Edgewise Therapeutics: Strong Open Label Data Makes For A Bullish Signal

May 10, 2024, 8:00 AM EDT - 1 year ago

Edgewise Therapeutics to Present at the RBC Capital Markets Global Healthcare Conference on May 15, 2024

May 9, 2024, 8:00 AM EDT - 1 year ago

Edgewise Therapeutics Reports First Quarter 2024 Financial Results and Recent Business Highlights

May 7, 2024, 8:00 AM EDT - 1 year ago

Edgewise Therapeutics Appoints Arlene Morris to its Board of Directors

May 6, 2024, 8:00 AM EDT - 1 year ago

Edgewise Therapeutics Doses First Patient in Phase 2 CIRRUS-HCM Trial of EDG-7500 in Obstructive Hypertrophic Cardiomyopathy (HCM)

Apr 23, 2024, 8:00 AM EDT - 1 year ago

Edgewise Receives European Medicines Agency (EMA) Orphan Drug Designations for Sevasemten (EDG-5506) for the Treatment of Becker and Duchenne Muscular Dystrophies

topstockalerts Dec. 25 at 3:26 PM

After Hours Top Gainers PT2 $INDP $SIDU $FMFC $IZM $EWTX

0 · Reply

SharpeRatioS Dec. 25 at 8:37 AM

$EWTX The valuation debate now centers on reliability of delivery, given the heightened sensitivity to timeline slippage. Delivery cadence is becoming the real competitive edge.

0 · Reply

WallStreetBuyDip Dec. 25 at 4:23 AM

0 · Reply

WallStreetBuyDip Dec. 25 at 4:02 AM

0 · Reply

Ohzipit Dec. 25 at 12:40 AM

$EWTX Raymond James -We Usually Do Gifts in the Evening, but Glad We Opened This One Early; Reiterate Strong Buy

1 · Reply

topstockalerts Dec. 24 at 10:37 PM

Top Gainers PT2 $INDP $SIDU $FMFC $IZM $EWTX

0 · Reply

topstockalerts Dec. 24 at 8:48 PM

After Hours Top Gainers PT2 $INDP $SIDU $FMFC $IZM $EWTX

0 · Reply

AStrokeOfLuck Dec. 24 at 6:45 PM

$EWTX

0 · Reply

topstockalerts Dec. 24 at 6:23 PM

Top Gainers PT2 $INDP $SIDU $FMFC $IZM $EWTX

0 · Reply

topstockalerts Dec. 24 at 5:57 PM

$EWTX heading for a strong close..

0 · Reply

StocktwitsNews Dec. 24 at 5:25 PM

Edgewise Therapeutics Stock Jumps After Trial Update For Genetic Heart Disease — Wall Street Eyes A Potential Standout $EWTX $IWMW $AVUS https://stocktwits.com/news/equity/markets/edgewise-therapeutics-stock-jumps-after-trial-update-for-genetic-heart-disease/cLetbZlREvN

2 · Reply

S_Franconi Dec. 24 at 3:52 PM

$EWTX

0 · Reply

topstockalerts Dec. 24 at 3:52 PM

$EWTX curling back up

0 · Reply

Trainguy1 Dec. 24 at 3:44 PM

$EWTX Yasmeen Rahimi from Piper Sandler is an aggressive, yet realistic stock analyst. She has a five out of five star rating according to TipRanks. Last month Yasmeen set a 1-year target price of $51/share for EWTX. I think given today’s news, the SP should settle at a new plateau in the high $20’s. Keep in mind that EWTX’s cash runway exceeds $1/2 billion, and is expected to support the company’s cash needs through the launch of Sevasemten for Becker’s muscular distrophy.

2 · Reply

S_Franconi Dec. 24 at 3:40 PM

$EWTX Thank you EWTX!

0 · Reply

topstockalerts Dec. 24 at 3:22 PM

Edgewise Therapeutics reported positive updates from its ongoing Phase 2 CIRRUS-HCM trial of EDG-7500 for hypertrophic cardiomyopathy. The drug was generally well tolerated, with no clinically meaningful reductions in left ventricular ejection fraction, a key potential advantage over competing cardiac myosin inhibitors linked to systolic dysfunction risk. In Part D of the study, which has enrolled more than 40 patients, about 70% reached doses of 100 mg or higher. Among 20 patients who completed 12 weeks of dosing before the Dec. 23 data cutoff, EDG-7500 maintained a favorable safety profile, with no ejection fraction falling below 50%. Management highlighted strong patient and physician interest, exceeding year-end enrollment goals. Edgewise previously reported positive results from Parts B and C, showing improvements in key HCM biomarkers and clinical measures. $EWTX

0 · Reply

ParabolicalSpartan Dec. 24 at 3:11 PM

What is happening to ticker UPC ?! Looks like they are SQUEEZING ticker UPC up next UPC is breaking out like crazy.. Only 500k float. All eyes on UPC now it seems >> $AMCI $SIDU $CREV $EWTX <<

0 · Reply

chrsc Dec. 24 at 2:37 PM

$EWTX the price action lately really is crazy. all over the place!

1 · Reply

judgeyoung2 Dec. 24 at 2:28 PM

$EWTX it was moving 20% randomly but it can’t even move 5% with news out 🙄

0 · Reply

Trainguy1 Dec. 24 at 2:11 PM

$EWTX Read this paragraph all the way to the end. "Furthermore, in Part D, continuous active cardiac monitoring was conducted for four weeks during screening and for two weeks following each dose escalation. More than 300 ambulatory cardiac monitoring devices have been deployed to participants, capturing over 2,600 patient-days of active cardiac monitoring, during which no clinically detectable AF or atrial flutter has been observed. A single adverse event of new onset AF was reported; this event occurred in an oHCM participant who was not on active cardiac monitoring at the time and who had a history of arrhythmias, including supraventricular tachycardia. The investigator deemed the event as not related to study drug."

1 · Reply

PnLGlowX_1677 Dec. 24 at 2:07 PM

$EWTX small cap biotech sleeping tight range asymmetry if volume ignites

0 · Reply

S_Franconi Dec. 24 at 1:35 PM

$EWTX "I'm excited about the advances we've made in Part D of the CIRRUS-HCM trial, where we've exceeded our year-end enrollment goal, highlighting continued enthusiasm for the program from patients and physicians" said Kevin Koch, Ph.D., President and Chief Executive Officer. "I'm especially pleased with EDG-7500's safety profile to date, and the lack of clinically relevant drops in ejection fraction, or any ejection fraction drops below 50%. A major focus of 2026 will be refining our development strategy to deliver the best-in-disease therapeutic profile that EDG-7500 may offer to obstructive and nonobstructive HCM patients." https://investors.edgewisetx.com/news/news-details/2025/Edgewise-Therapeutics-Announces-Completion-of-the-EDG-7500-CIRRUS-HCM-Phase-2-Parts-B-and-C-and-Favorable-Interim-Safety-Results-from-the-Ongoing-Part-D-Study-in-Hypertrophic-Cardiomyopathy/default.aspx

0 · Reply

Market Cap	2.30B
Revenue (ttm)	0.00
Net Income (ttm)	-133.81M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	3,623,200
Avg Vol	1,441,336
Day's Range	N/A - N/A
Shares Out	105.87M
Stochastic %K	99%
Beta	0.26
Analysts	Strong Sell
Price Target	$38.17